CSBR
Champions Oncology, Inc.
Biotechnology · Healthcare · United States
4.81
close · 2026-10-29
value
24
cheaper than peers24
quality
49
stronger fundamentals49
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.19× | 97 |
| forward P/E | 48.10× | 14 |
| price to book | 17.18× | 13 |
| EV to EBITDA | 199.60× | 9 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -3.8% | 77 |
| return on equity | -30.0% | 66 |
| revenue growth | 12.0% | 43 |
| debt to equity | 113.0% | 21 |
4 of 4 measures available
Facts
| market cap | $67M |
| free cash flow | -$4.3M |
| employees | 214 |
| first trade | 2007-02-02 |
| next earnings | 2026-09-10 |
| fundamentals updated | 2026-09-10 |
Annual history
| measure | 2026 | 2025 | 2024 | 2023 |
| diluted eps | -0.08 | 0.33 | -0.54 | -0.39 |
| free cash flow | -$5.0M | $7.0M | -$7.0M | $1.1M |
| net income | -$1.2M | $4.7M | -$7.3M | -$5.3M |
| revenue | $59.4M | $56.9M | $50.2M | $53.9M |
| unusual items | -$111,000 | -$293,000 | -$435,000 | -$807,000 |